Pharmaceutics (Nov 2022)

Dual Functionalized Liposomes for Selective Delivery of Poorly Soluble Drugs to Inflamed Brain Regions

  • Sabrina Giofrè,
  • Antonio Renda,
  • Silvia Sesana,
  • Beatrice Formicola,
  • Barbara Vergani,
  • Biagio Eugenio Leone,
  • Vanna Denti,
  • Giuseppe Paglia,
  • Serena Groppuso,
  • Valentina Romeo,
  • Luca Muzio,
  • Andrea Balboni,
  • Andrea Menegon,
  • Antonia Antoniou,
  • Arianna Amenta,
  • Daniele Passarella,
  • Pierfausto Seneci,
  • Sara Pellegrino,
  • Francesca Re

DOI
https://doi.org/10.3390/pharmaceutics14112402
Journal volume & issue
Vol. 14, no. 11
p. 2402

Abstract

Read online

Dual functionalized liposomes were developed to cross the blood–brain barrier (BBB) and to release their cargo in a pathological matrix metalloproteinase (MMP)-rich microenvironment. Liposomes were surface-functionalized with a modified peptide deriving from the receptor-binding domain of apolipoprotein E (mApoE), known to promote cargo delivery to the brain across the BBB in vitro and in vivo; and with an MMP-sensitive moiety for an MMP-triggered drug release. Different MMP-sensitive peptides were functionalized at both ends with hydrophobic stearate tails to yield MMP-sensitive lipopeptides (MSLPs), which were assembled into mApoE liposomes. The resulting bi-functional liposomes (i) displayed a −5 cm/min; (iii) when exposed to functional MMP2 or 9, efficiently released an encapsulated fluorescein dye; (iv) showed high biocompatibility when tested in neuronal cultures; and (v) when loaded with glibenclamide, a drug candidate with poor aqueous solubility, reduced the release of proinflammatory cytokines from activated microglial cells.

Keywords